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Introduction
Phthalates are widely used as plasticizers in, 
for example, toys, cosmetics, food packaging, 
medical equipment, and building materials 
(Wittassek et al. 2011). Some of the most 
commonly used phthalates have been shown 
to cause outcomes in rats consistent with 
antiandrogenic effects, such as impaired sper-
matogenesis, undescended testes (cryptor-
chidism), and reduced anogenital distance 
(Borch et al. 2006; Foster 2006; Howdeshell 
et al. 2007).
Associations of early phthalate expo-
sures with allergic asthma and reproductive 
and behavioral outcomes suggest that the 
fetus, neonate, and infant may be particu-
larly vulnerable to endocrine-disrupting 
effects of these compounds (Bergman et al. 
2012; Bornehag and Nanberg 2010; Main 
et al. 2006; Miodovnik et al. 2011; Swan 
et al. 2005, 2010; Whyatt et al. 2012). 
Despite these concerns, data on phthalate 
exposure levels during this period of life are 
sparse (Adibi et al. 2008; Enke et al. 2013; 
Sathyanarayana et al. 2008a, 2008b). Some 
studies have reported extremely high exposure 
to di(2-ethylhexyl) phthalate (DEHP) during 
hospitalization in preterm children (Silva 
et al. 2006; Su et al. 2012; Weuve et al. 
2006), suggesting a risk of adverse health 
effects in this group as gonadal development 
is not completed (Rey and Josso 2013) and 
detoxification processes are still immature 
(Coughtrie et al. 1988; Tan et al. 1990).
In the present longitudinal study, we 
investigated urinary phthalate exposure from 
birth to 14 months of age in a group of full-
term (FT) and preterm (PT) infants, covering 
periods of hospitalization and home stay. We 
also assessed whether these exposure levels 
exceeded European Food Safety Authorities 
(EFSA) guidelines for tolerable daily intakes 
(EFSA 2005a, 2005b, 2005c).
Materials and Methods
Study population. As part of the Finnish 
Minipuberty study, a total of 173 mothers 
either with a normal singleton pregnancy or 
with a threat of premature delivery before 
37.0 weeks of gestation were recruited in 
consecutive order inside these cohorts between 
August 2006 and March 2008 at Kuopio 
University Hospital, Finland. After delivery, 
infants of these mothers were recruited for 
the study, which included clinical examina-
tions and sample collection at child’s age of 
1–3 days (D1–3), 7 days (D7), and 1, 2, 3, 4, 
5, and 6 months (M1–M6), and finally at the 
corrected age of 14 months [M14; 14 months 
from the expected date of delivery, approxi-
mately 100 weeks of postmenstrual (PM) age, 
where PM age was defined as sum of gesta-
tional age at birth plus postnatal age at exami-
nation to signify the “true” biological age of 
the infant]. Altogether, 125 children of 113 
mothers completed the follow-up, and these 
included 58 FT (29 boys) and 67 PT (33 
boys) infants (Table 1). A total of 894 urine 
samples were obtained at 1,067 visits. Two 
FT infants were twin sisters; nine PT boys 
and 11 PT girls were twins, and three PT girls 
were triplets. FT infants stayed at the hospital 
2–18 days (mean, 4.3) while PT infants were 
hospitalized 3–156 days (mean, 39.6), up 
to 38–42 PM weeks (Kuiri-Hänninen et al. 
2011a, 2011b).
Ethics. Both parents gave informed 
consent at initial recruitment and at follow-
up at M14. The study was approved by the 
Ethics Committee of the Northern-Savo 
Health Care District.
Sample collection. Spot urine samples 
were collected in polyethylene urine collection 
bags (Paediatric Urine Collector, Unomedical, 
Lejre, Denmark, and U-Bag Pediatric, Mabis 
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Background: Some phthalates have shown antiandrogenic effects in rat offspring. Premature 
infants may be exposed to high amounts of specific phthalates during hospitalization, and thus are 
potentially at risk.
oBjective: We evaluated longitudinal phthalate exposure and metabolism in full-term (FT) and 
preterm (PT) infants.
Methods: Fifty-eight FT and 67 PT (gestational age, 24.7–36.6 weeks) infants were recruited 
at birth and followed until 14 months (nine times). Urinary concentrations of metabolites of 
diethyl phthalate (DEP), dibutyl phthalate isomers (DiBP and DnBP), butylbenzyl phthalate 
(BBzP), di(2-ethylhexyl) phthalate (DEHP), and diisononyl phthalate (DiNP) were measured in 
894 samples. Daily intake and a hazard index for antiandrogenic effects were estimated, and excre-
tion patterns of DEHP and DiNP metabolites were analyzed.
results: Metabolites of BBzP, DiNP, and DEHP were 5–50 times higher at day 7 (D7) and 
month 1 (M1) in PT than in FT infants. Thereafter, metabolite concentrations were similar 
between the two groups. The estimated hazard index for combined DiBP, DnBP, BBzP, and 
DEHP exposures 7 days after birth exceeded the antiandrogenic threshold in > 80% of PT and 
> 30% of FT infants, and after M2, in 30% of all infants. The excretion pattern of DEHP and 
DiNP metabolites changed with age.
conclusion: Most PT infants and approximately one-third of healthy FT newborns were exposed 
to phthalates during early life at a potentially harmful level according to the European Food Safety 
Authority’s recommended limits of daily exposure. Changes in the relative proportions of secondary 
phthalate metabolites over time were consistent with maturation of infant metabolic pathways 
during the first year of life. Further research is needed on the health effects of phthalate exposures 
and the influence of changes in metabolic capacity in neonates and infants.
citation: Frederiksen H, Kuiri-Hänninen T, Main KM, Dunkel L, Sankilampi U. 2014. A 
longi tudinal study of urinary phthalate excretion in 58 full-term and 67 preterm infants 
from birth through 14 months. Environ Health Perspect 122:998–1005; http://dx.doi.
org/10.1289/ehp.1307569
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Healthcare, Waukegan, IL, USA) or by clean 
catch into polystyrene plastic cups (Econo 
Plastic Container, Huhtamäki OyJ, Finland) 
at every visit, and transported in 10-mL 
polypropene vials (Linkoputki, Mekalasi Oy, 
Finland). Urinary creatinine was measured 
by an enzymatic method before storage at 
–70°C in 3-mL polypropene vials (Mekamini, 
Mekalasi Oy, Finland).
Chemical analysis. Twelve primary 
and secondary metabolites of six phthalate 
diesters [diethyl phthalate (DEP), diisobutyl 
phthalate (DiBP), di-n-butyl phthalate 
(DnBP), butylbenzyl phthalate (BBzP), 
DEHP, and diisononyl phthalate (DiNP)] 
were analyzed. The total (sum of free and 
conjugated) content of monoethyl phthalate 
(MEP), monoisobutyl phthalate (MiBP), 
mono-n-butyl phthalate (MnBP), mono-
benzyl phthalate (MBzP), mono(2-ethylhexyl) 
phthalate (MEHP), mono(2-ethyl-5-hydroxy-
hexyl) phthalate (MEHHP), mono(2-ethyl-
5 - o x o h e x y l )  p h t h a l a t e  ( M E O H P ) , 
mono(2-ethyl-5-carboxypentyl) phthalate 
(MECPP), monoisononyl phthalate (MiNP), 
mono(hydroxyisononyl) phthalate (MHiNP), 
mono(oxoisononyl) phthalate (MOiNP), and 
mono(carboxyisooctyl) phthalate (MCiOP) 
was analyzed by isotope dilution liquid chro-
matography tandem mass spectrometry with 
preceding enzymatic deconjugation followed 
by automatic solid phase extraction. The 
method details have been described previ-
ously (Frederiksen et al. 2010). Samples were 
analyzed in 22 batches during 8 weeks. Each 
batch included standards, 40 samples, two 
blanks, two pooled urine control samples, 
and two pooled urine control samples spiked 
with standards to an added concentration of 
10 ng/mL. The recovery was > 90% for all 
analytes and the interday variation, expressed 
as relative standard deviation (RSD), was 
< 3% for all analytes except MiBP (7%) and 
MnBP (9%). Limits of detection (LOD) are 
shown in Table 2.
Statistics. We measured one hydroxyl-
ated monoester and three oxidized secondary 
metabolites of DEHP and DiNP, respectively. 
To simplify data analysis, we calculated the 
molar sum of DEHP metabolites (MEHP, 
MEHHP, MEOHP, and MECPP) and DiNP 
metabolites (MiNP, MHiNP, MOiNP, and 
MCiOP) by multiplying the molar sums with 
the molecular weights of DEHP and DiNP, 
respectively (∑DEHPm and ∑DiNPm in 
nanograms per milliliter, respectively).
Medians ,  percent i les ,  and ranges 
(minimum–maximum) of all measured 
phthalate concentrations were computed. 
All urinary metabolite concentrations 
< LOD were set to 0.0 except for the 
analyses of intraclass correlation coefficients 
(ICCs) or if ln-transformation was used; 
in these cases, data < LOD were set to 
LOD divided by the square root of 2.
We also provide descriptive statistics 
for samples after adjustment for urinary 
creatinine to account for dilution. However, 
because a child’s urinary creatinine 1–3 days 
after birth reflects maternal creatinine (Matos 
et al. 1998), we excluded samples collected on 
D1–3 from this analysis.
Within- and between-person variance as 
well as ICCs were calculated. The ICC takes 
a value between 0 and 1 and reflects the rela-
tionships between the within- and between-
subject variance. ICCs were classified as weak 
(< 0.4), moderate (0.4–0.6), or good (> 0.6) 
(Philippat et al. 2013).
For each child i we estimated the daily 
intake (DI) (micrograms per kilogram 
per day) of each phthalate diester p at 
sampling time t as:
DIpit = [Σ
n
k = 1 (UEkit /MWk)] × MWp  
 × CEsmoothed /(FUEp × BWit), [1]
where UEkit represents the creatinine-adjusted 
urinary concentration (micrograms per gram 
creatinine) of metabolite k in child i at time t, 
MWk is the molecular mass of metabolite k 
(micrograms per micromole), MWp is the 
molecular mass of diester p (micrograms per 
micromole), and CEsmoothed is the estimated 
average 24-hr urinary creatinine excretion 
(grams per day) based on a study of newborns 
at 28–42 weeks of gestation (Al-Dahhan 
et al. 1988). FUEp is the estimated fraction 
of diester p excreted in urine, and BWit is the 
body weight (kilograms) of child i at time t. 
We assumed the following values of FUEp 
based on studies of adults after oral intake of 
deuterium labeled phthalate diesters: 84% of 
DnBP excreted as MnBP, 70.3% of DiBP 
as MiBP, 70% of BBzP as MBzP, 45.3% 
of DEHP as DEHP metabolites (MEHP, 
MEHHP, MEOHP, and MECPP), and 
Table 1. Birth characteristics: n = 125 [n (%) or mean ± SD (range)].
FT infants PT infants
Boys
n (%) 29 (50.0) 33 (49.3)
Gestational weeks 39.8 ± 1.37 (37.1–42.1) 31.8 ± 3.26 (24.7–36.6)
Birth weight (g) 3,274 ± 741 (1,910–4,420) 1,693 ± 548 (550–2,850)
Birth length (cm) 49.1 ± 2.88 (42–53) 41.3 ± 4.6 (30–48)
Days at hospital 4.9 ± 4.16 (2–18) 42.9 ± 32.0 (7–131)
Girls
n (%) 29 (50.0) 34 (50.7)
Gestational weeks 39.5 ± 1.33 (37.0–41.7) 32.9 ± 3.03 (24.7–36.7)
Birth weight (g) 3,373 ± 630 (2,070–4,750) 1,765 ± 522 (530–2,720)
Birth length (cm) 49.2 ± 2.61 (44–54) 41.8 ± 4.27 (29–47)
Days at hospital 3.8 ± 2.26 (2–12) 36.4 ± 31.4 (3–156)
Table 2. Urinary phthalate metabolite concentrations (ng/mL) in serial samples from birth to 14 months of age in 58 FT (n = 432 samples) and 67 PT (n = 462 
samples) infants.
Phthalate 
metabolite LOD
FT PT
n > LOD Percent > LOD Min 10th Median 90th Max n > LOD Percent > LOD Min 10th Median 90th Max
MEP 0.53 432 100.0 0.82 3.46 10.7 49.1 486 462 100.0 0.71 3.51 11.9 44.0 190
MiBP 1.43 431 99.8 < LOD 7.45 21.0 62.3 337 462 100.0 3.21 8.40 23.3 92.4 5,648
MnBP 1.10 431 99.8 < LOD 4.96 15.2 51.3 156 462 100.0 1.43 5.89 15.5 47.3 6,533
MBzP 1.14 432 100.0 1.85 6.66 24.6 118.0 1,985 462 100.0 2.13 8.66 43.1 244.0 1,155
MEHP 0.14 329 76.2 < LOD < LOD 0.44 2.11 849 396 85.7 < LOD < LOD 0.99 27.4 1,379
MEHHP 0.91 407 94.2 < LOD 1.27 5.01 26.0 480 451 97.6 < LOD 1.63 8.62 163.0 6,934
MEOHP 0.67 414 95.8 < LOD 1.06 3.90 15.3 351 452 97.8 < LOD 1.50 6.12 86.4 4,010
MECPP 0.55 432 100.0 0.75 3.74 10.7 40.2 1,366 462 100.0 0.81 5.85 17.9 668.0 26,011
ΣDEHPm 8.83 26.5 109.0 4,032 12.3 45.3 1284.0 46,488
MiNP 0.61 11 2.5 < LOD < LOD < LOD 0.18 2.88 49.0 10.6 < LOD < LOD < LOD 0.65 93.0
MHiNP 0.26 212 49.1 < LOD < LOD < LOD 2.16 27.1 312 67.5 < LOD < LOD 0.61 6.46 135
MOiNP 0.25 200 46.3 < LOD < LOD < LOD 1.33 10.4 301 65.2 < LOD < LOD 0.47 4.92 125
MCiOP 0.11 427 98.8 < LOD 0.29 1.32 5.40 58.2 458 99.1 < LOD 0.50 2.37 29.8 493
ΣDiNPm 2.36 11.6 107 4.74 62.7 1,035
Abbreviations: ΣDEHPm, the sum of DEHP metabolites; ΣDiNPm, the sum of DiNP metabolites; LOD, limit of detection; Max, maximum; Min, minimum. 10th and 90th are percentiles.
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30% of DiNP as DiNP metabolites (MiNP, 
MHiNP, MOiNP, and MCiOP) (Anderson 
et al. 2001, 2011; Koch et al. 2012). For 
DEP we assumed an FUE of 69% (excreted 
as MEP) based on previous estimate for DnBP 
excretion. This estimate has often been used, 
because a human kinetic study on DEP is 
missing (Koch and Calafat 2009). To obtain a 
single median and selected percentile estimates 
for each phthalate at each sampling time (D7 
through M14) according to PT or FT birth, 
estimates of DI for each child at time t were 
calculated as centiles. DI was not estimated 
for infants at time point D1–3, because creati-
nine is known to be elevated due to maternal 
contamination (Matos et al. 1998).
We estimated a hazard quotient (HQ) 
for phthalate diesters based on tolerable 
DI (TDI) values established by the EFSA 
(2005a, 2005b, 2005c). TDI values for 
DnBP [10 μg/kg/day, ~ lowest observed 
adverse effect level (LOAEL) with an uncer-
tainty factor of 200], BBzP [500 μg/kg/day, 
~ no observed adverse effect level (NOAEL) 
with an uncertainty factor of 100], and 
DEHP (50 μg/kg/day, ~ NOAEL with 
an uncertainty factor of 100) are based on 
experimental animal studies. Because DiBP 
has shown effects similar to those of DnBP 
(Borch et al. 2006), TDI for DnBP was 
used to calculate HQ for DiBP. We divided 
estimated DIs by their corresponding TDI 
to derive HQs for phthalate diesters with 
evidence of antiandrogenic effects—DiBP, 
DnBP, BBzP, and DEHP—and combined 
the HQ estimates for these compounds to 
derive a single estimated hazard index (HI) 
for each infant (Koch et al. 2011; Soeborg 
et al. 2012):
 HIt = Σ
n
p = 1 (DIpt /TDIp), [2]
where DIpt is the estimated average daily 
intake of diester p (micrograms per kilogram 
per day) at time t, and TDIp is the EFSA 
guideline value (micrograms per kilogram 
per day) for diester p (as indicated above). 
HI = 1 is the antiandrogenic threshold, and 
a level > 1 indicates a potential risk of anti-
androgenic effects.
We used mixed-models analysis for statis-
tical testing to account for the correlation 
structure because of the repeated measure-
ments and multiple births in the cohort. We 
derived between- and within-group compari-
sons of phthalate metabolite concentrations, 
and estimated differences according to sex, 
hospitalization at the time of sampling 
(yes/no), breastfeeding (none, partial, or 
full), and child’s weight at sampling. Data 
were analyzed according to calendar age 
(i.e., time from birth) and, to account for 
the immaturity in the PT infants, according 
to PM age (defined as sum of gestational 
age at birth plus postnatal age at examina-
tion) categorized into intervals (30.1–34.0, 
34.1–38.0, 38.1–42.0, 42.1–46.0, 46.1–50.0, 
50.1–54.0, 54.1–58.0, 58.1–62.0, 62.1–68.5, 
and 96–106 PM weeks) corresponding to 
sampling times at D1–3, D7, M1–M6, 
and the corrected age of M14, respectively. 
Birth group (PT or FT), time point (or PM 
age category), sex, breastfeeding, hospital-
ization, and weight were modeled as fixed 
effects, whereas subject and an indicator for 
multiple births were modeled as random 
effects. Associations between the concen-
trations of different phthalate metabolites 
and estimated DI were also analyzed using 
the mixed model. We report standardized 
coefficients of natural log (ln)–transformed 
phthalate metabolite concentrations, which 
are interpreted as correlation coefficients. 
p-Values < 0.05 were considered statistically 
significant. SPSS software version 19.0 (SPSS 
Inc., IBM, Chicago, IL, USA) was used for 
statistical analyses.
Results
Phthalate concentrations. At least one metabo-
lite of each of the six phthalates was detectable 
in virtually all urine samples of both FT and 
PT infants, indicating that all infants were 
exposed to DEP, BBzP, and DEHP, and 
that almost all infants were exposed to DiBP, 
DnBP, and DiNP at all time points. Only 
in one single urine sample were metabolites 
of DiBP or DnBP not detectable, whereas 
five urine samples did not contain measur-
able concentrations of any of the DiNP 
metabolites (Table 2). ∑DEHPm had the 
highest median concentration in both groups, 
followed by MBzP, MiBP, MnBP, MEP, 
and ∑DiNPm. Except for MEP and MnBP, 
PT infants had significantly higher median 
concentrations than did FT infants for all 
metabolites (p < 0.05 for MiBP; otherwise 
p < 0.001). Creatinine-adjusted phthalate 
metabolite concentrations were about 
10 times higher than measured concentra-
tions, with similar differences between PT and 
FT infants as in the unadjusted values (see 
Supplemental Material, Table S1).
Concentrations of all metabolites were 
correlated, indicating that infants were 
simultaneously exposed to multiple phthal-
ates. The weakest correlations were observed 
between MEP and MBzP, ∑DEHPm, and 
∑DiNPm (parameter estimates from the stan-
dardized mixed model 0.41, 0.25, and 0.30, 
Figure 1. Within-subject variation of urinary phthalate metabolite levels in 58 FT infants (307 samples) 
from M1–M6 and 67 PT infants (290 samples) from M2–M6 for MEP, MiBP, MnBP, MBzP, ∑DEHPm, 
and ∑DiNPm. Vertical lines with dots represent individual samples of the same infant (y-axis) versus 
the infant’s mean phthalate metabolite level (x-axis). All concentrations were ln-transformed. Phthalate 
metabolite concentrations for PT infants at M1 were not included, because PT infants at M1 mostly were 
hospitalized, whereas only seven and five infants still were hospitalized at M2 and M3, respectively.
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respectively); between MiBP and ∑DEHPm 
and ∑DiNPm (0.31 and 0.38, respectively); 
and between MnBP and ∑DEHPm and 
∑DiNPm (0.36 and 0.45, respectively). 
Correlations among all other metabolites were 
stronger, with parameter estimates ranging 
from 0.52 (MiBP and MBzP) to 0.87 (MiBP 
and MnBP). From around M1 for FT and 
M2 for PT infants, each infant tended to stay 
within his or her trajectory of low or high 
exposure (Figure 1), although the ICC was 
low to moderate for most metabolites in 
both FT and PT infants (see Supplemental 
Material, Table S2). The highest ICCs were 
in general observed from M1 to M6 in FT 
infants and from M2 to M6 in PT infants 
indicating consistent exposure in this period, 
but ICCs decreased if M14 was included.
Factors associated with urinary phthalate 
metabolite levels. Sex and breastfeeding were 
not significantly associated with urinary 
phthalate levels (see Supplemental Material, 
Table S3). Therefore, these factors were not 
included in the subsequent models. MEP, 
MiBP, and MnBP excreted from D1–3 to 
M14 showed a similar pattern for FT and 
PT infants except for MEP and MnBP at 
D7, for which PT infants had significantly 
higher excretion (Figure 2). Concentrations 
of other phthalate metabolites were signifi-
cantly higher in PT infants compared with 
FT infants in D1–3, D7, and M1 samples 
for MBzP and ∑DEHPm, and in D7 and 
M1 samples for ∑DiNPm (Figure 2). 
Significantly higher concentrations of MBzP 
in M1 and M2 samples (p < 0.01), and of 
∑DEHPm and ∑DiNPm in M1, M2, and 
M3 samples (p < 0.01) were estimated for 
hospitalized PT infants compared with PT 
infants at home (see Supplemental Material, 
Figure S1). However, differences between 
FT and PT infants in MBzP and ∑DEHPm 
(at D1–3 and D7) and ∑DiNPm (at D7 
and M1) concentrations remained statisti-
cally significant even after adjustment for 
 hospitalization (Figure 2).
After discharge from hospital, all metabo-
lites except MBzP in FT infants increased 
significantly from D7 to M14 (p < 0.05, 
adjusted for weight). In discharged PT 
infants, a similar, significant increase was 
observed in all metabolites except MEP from 
M1 to M14 (p < 0.01, adjusted for weight) 
(see Supplemental Material, Figure S1).
Urinary phthalate metabolites by PM age. 
MBzP, ∑DEHPm, and ∑DiNPm concentra-
tions in PT infants were significantly higher 
in PM weeks 30.1–34.4 and 34.1–38.0 than 
were concentrations in later PM weeks in 
both PT and FT infants (p < 0.01, adjusted 
for weight) (see Supplemental Material, 
Figure S2). Furthermore, concentrations of 
∑DEHPm in samples collected at PM weeks 
46.1–50.0 and 54.1–58.0 and of ∑DiNPm 
in samples collected at PM weeks 42.1–46.0 
through 54.1–58.0 were significantly higher 
in PT compared with FT infants (see 
Supplemental Material, Figure S2).
Urinary phthalate excretion pattern. The 
proportion of monoester levels (MEHP and 
MiNP) relative to other DEHP and DiNP 
metabolites, respectively, was stable during the 
whole follow-up (Figure 3). A considerable 
change in the excretion pattern of secondary 
metabolites was observed by increasing 
maturation. The relative proportion of the 
carboxylated metabolites decreased signifi-
cantly by PM age from an average of 66% to 
35% MECPP in FT and PT infants, and from 
78% to 58% MCiOP in FT and from 71% 
to 55% MCiOP in PT infants. The propor-
tions of other oxidized metabolites increased 
in the same period: hydroxyl ated metabolites 
from an average of 18% to 39% (MEHHP) 
and from 13% to 27% (MHiNP), and the 
keto-modified metabolites from 13% to 20% 
(MEOHP) and from 12% to 15% (MOiNP). 
In some samples, only carboxylated metabo-
lites were detectable in concentrations above 
LODs. There was no statistically significant 
association of excretion patterns with esti-
mated absolute exposure levels or sex (data 
not shown).
Daily intake (DI), HQ, and HI estimates. 
Median estimated DIs of phthalate diesters 
from D7 to M14 are shown in Figure 4 (see 
Supplemental Material, Table S4, for corre-
sponding numeric data). A constant estimated 
DI over time was observed for all phthalates, 
except a significant decrease of exposure 
to BBzP, DEHP, and DiNP in PT infants 
from D7 to M2–3. The median DIs of DEP, 
DiBP, and DnBP did not differ significantly 
between FT and PT infants over time. In 
Figure 2. Median levels (error bars indicate the 25th–75th percentiles) of urinary phthalate metabolites in 
432 samples (D1–3, n = 32; D7, n = 50; M1, n = 53; M2, n = 54; M3, n = 50; M4, n = 51; M5, n = 50; M6, n = 49; 
M14, n = 43) of FT and 462 samples (D1-3, n = 41; D7, n = 39; M1, n = 48; M2, n = 51; M3, n = 59; M4, n = 57; 
M5, n = 61; M6, n = 61; M14, n = 45) of PT infants according to age [day (D) and month (M)].
Symbols indicate statistical significance for group difference in the mixed-model analysis adjusted for weight (*p < 0.05, 
**p < 0.01, and #p < 0.001).
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contrast, median DIs of BBzP, DEHP, and 
DiNP concentrations were significantly 
higher in PT than in FT newborns from D7 
to M2 (data not shown).
Median estimated HQs based on TDI 
values for DiBP, DnBP, BBzP, and DEHP 
are shown in Figure 4 and Supplemental 
Material, Table S4. At D7, > 80% of the PT 
infants exceeded the antiandrogenic threshold 
(HI > 1), whereas approximately 30% of the 
FT infants (and the PT infants from M2) 
exceeded the threshold during the entire first 
year of life.
Discussion
To our knowledge, this is the first compre-
hensive longitudinal study of FT and PT 
infants from birth through 14 months of age, 
which documents a considerable exposure 
of all infants to multiple phthalates with an 
endocrine-disrupting potential. Our findings 
regarding estimated DI and accumulated HI 
raise concern. Most PT children and approxi-
mately one-third of FT children exceed the 
EFSA safety margin calculated for anti-
androgenic effects, in particular shortly after 
birth. Such safety margins are estimated based 
on toxicological studies with rats defining 
exposure limits for either no observed 
effects or lowest dose with observed effect. 
Thus, our results raise concern because the 
observed phthalate exposures may put these 
infants at risk.
Epidemiological studies in humans have 
reported that phthalate exposure prenatally 
and in early life is associated with changes in 
infant sex hormones and decreased anogenital 
distance (AGD) (Main et al. 2006; Swan 
et al. 2005), allergic asthma (Bornehag and 
Nanberg 2010), and changes in sex-specific 
behavioral patterns (Miodovnik et al. 2011; 
Swan et al. 2010; Whyatt et al. 2012). This 
is corroborated by numerous animal experi-
ments showing decreased AGD and testic-
ular testestorone production after in utero 
exposure (Borch et al. 2006; Foster 2006; 
Howdeshell et al. 2007).
It has previously been shown that prema-
ture children are highly exposed to DEHP 
from medical equipment (Silva et al. 2006; 
Su et al. 2012; Weuve et al. 2006). It was 
assumed that this exposure was restricted to 
DEHP (Weuve et al. 2006). However, our 
study shows that higher phthalate exposure 
also occurred among hospitalized FT infants 
and was not restricted to DEHP. Although 
concentrations of metabolites in urine suggest 
that the Finnish PT infants in our popula-
tion were exposed to DEP, DiBP, and DnBP 
at levels similar to those of the FT infants 
at hospital and at home, they were signifi-
cantly more exposed to BBzP, DEHP, and 
DiNP during hospitalization compared with 
PT infants after discharge from hospital: The 
neonatal intensive care unit was the likely 
exposure source. After discharge, exposure 
patterns for BBzP, DEHP, and DiNP were 
similar for PT and FT infants. Regional 
differences may exist in the use of phthalate 
diesters in medical equipment. However, 
domestic exposure also needs to be addressed 
when planning preventive measures. Urinary 
phthalate metabolite concentrations increased 
with age, but the estimated DI per kilogram 
body weight remained constant over time. 
Diet has been pointed out as the main source 
of phthalate exposure, especially for DEHP 
(Wittassek et al. 2011). However, only 
low amounts of phthalate diesters or their 
metabolites have been quantified in human 
breast milk (Fromme et al. 2011; Main et al. 
2006) but especially low-molecular phthalates 
such as dimethyl phthalate, DEP, and DiBP 
have been observed in baby care products 
(Sathyanarayana et al. 2008b).
It is still debated whether urinary concen-
trations of phthalate metabolites should be 
adjusted for creatinine (Lorber et al. 2011) 
to correct for dilution. We did not use creati-
nine correction for the first 3 days because 
levels are elevated due to maternal contami-
nation (Matos et al. 1998). Thus, in our 
study, results from D1–3 were not included 
when analyzing data, which were creatinine 
corrected. Muscle mass in infants is extremely 
small, so creatinine-adjusted levels are 
extremely high. This should be kept in mind 
when comparing exposure levels in infants to 
those in older populations. During the first 
postnatal months, urinary dilution will show 
less variation due to a more consistent eating 
and sleeping pattern in newborns compared 
with older children. Creatinine correction 
may therefore not be as appropriate as in 
older populations.
Because exposure through breastfeeding is 
believed to be low (Fromme et al. 2011), and 
our study did not reveal statistically significant 
differences in phthalate exposure levels between 
breastfed and bottle-fed infants, exposure may 
occur through sources other than diet. The 
relatively constant DI in our study indicates 
Figure 3. The proportion of individual DEHP or DiNP metabolites versus the total sum of all measured DEHP 
metabolites (∑DEHPm) or DiNP metabolites (∑DiNPm) by PM age in 58 FT (~ 432 urine samples) and 67 PT 
infants (~ 462 urine samples). In seven FT and three PT samples, MECPP was the only metabolite of DEHP 
measured (MECPP/∑DEHPm = 100%), and in 201 FT and 135 PT samples MCiOP was the only metabolite of 
DiNP (MCiOP/∑DiNPm = 100%) measured.
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exposure sources such as personal care products 
and the general home environment. Phthalates 
are present in many consumer products 
(Buckley et al. 2012; Fromme et al. 2007; 
Sathyanarayana et al. 2008b), they sediment 
in house dust (Becker et al. 2004; Langer et al. 
2014), and exposure occurs through inges-
tion, inhalation, and dermal contact (Janjua 
et al. 2008; Langer et al. 2014; Wittassek et al. 
2011). Because infants share their mother’s 
environment, exposure levels measured after 
birth may also reflect antenatal exposure 
(Sathyanarayana et al. 2008a; Wittassek et al. 
2009). Both the prenatal and early postnatal 
periods are particularly vulnerable phases for 
reproductive development (Main et al. 2006; 
Swan et al. 2005).
Because phthalates have a short half-life 
in humans (Anderson et al. 2001, 2011; 
Koch et al. 2012), assessment of exposure 
levels is difficult. Concentrations of phthlate 
metabolites in urine are considered the best 
biomarker of exposure (Frederiksen et al. 
2010). However, variation in urinary dilution 
and phthalate exposures (Sathyanarayana 
et al. 2008b) leads to variation in phthalate 
concentrations among spot urine samples 
collected from the same individual, which was 
also observed in our study. However, a given 
infant tended to stay within low, medium, 
or high levels of exposures over time, which 
was in accordance with previous observa-
tions (Mouritsen et al. 2013). Although we 
observed low-to-moderate ICCs for most 
phthalates, our data indicate that the within-
subject variability was lower than the between-
subject variability. These ICCs were similar 
to previous ICCs in pregnant women (Adibi 
et al. 2008; Frederiksen et al. 2013). In young 
men, ICCs were similar for MEP, MiBP, 
MnBP, and BBzP but higher for ∑DEHPm 
and ∑DiNPm (Adibi et al. 2008; Frederiksen 
et al. 2013). This suggests a more constant 
phthalate exposure in infants and pregnant 
women than in young men. Highest ICCs 
were observed from M1 to M6 in FT infants 
and from M2 to M6 in PT infants, indicating 
a relatively consistent exposure during this 
period. Such consistency may be created by 
uniform diet (breast milk and/or formula) 
given regularly during the waking hours and 
a consistent home environment during the 
first months of life. ICCs decreased slightly 
at 14 months of age, perhaps indicating more 
variable sources of exposure during diet transi-
tion to more solid foods and to a more active 
and exploratory lifestyle, including mouthing 
of toys and objects.
Children with a relatively high exposure 
to one phthalate tended also to be highly 
exposed to the other five phthalates, and expo-
sures tended to be present at a relatively high 
level throughout infancy. Similar significant 
correlations were observed in several previous 
studies (Frederiksen et al. 2012; Koch et al. 
2011; Mieritz et al. 2012; Mouritsen et al. 
2013). This may be of biological significance 
because high simultaneous exposure may 
exceed a safe threshold. Our estimates of daily 
phthalate intakes, HQs, and HI are rough 
estimates and should be interpreted with 
caution. Urinary excretion fractions used 
to estimate daily intakes were derived from 
adult studies because they are not available 
for infants (Anderson et al. 2001, 2011; Koch 
et al. 2012). Likewise, we used estimates of 
the average excretion of creatinine based on 
24-hr urine collections from 60 infants with 
gestational age 27–40 weeks and postnatal 
age ranging from 3–68 days (Al-Dahhan et al. 
1988). Also, exposure measurements in the 
individual child vary over time. Thus, our data 
should be taken only as indicator of potential 
antiandrogenic effects. Thirty percent of all 
infants exceed the antiandrogenic threshold, 
and 80% of preterm babies during the first 
2–3 months of life. The same children will 
simultaneously be exposed to other envi-
ronmental chemicals (Kortenkamp and 
Faust 2010), which may act synergistically 
with phthalates. Thus, our observations 
raise concern.
Our study indicates a change during the 
first year of life in the detoxification metab-
olism of phthalates, which is mostly likely 
linked to physiological maturation processes 
in newborn infants. Carboxylated metabolites 
decreased and oxidized metabolites increased 
during the first year of life. A high proportion 
of the carboxylated metabolite MECPP has 
been reported before in newborns (2–5 days 
after birth) and preterm infants (Enke et al. 
2013; Silva et al. 2006). At 14 months of age, 
the urinary metabolite distribution pattern for 
DEHP and DiNP was comparable with the 
pattern in older children and adults (Becker 
Figure 4. Median daily intake (DI), hazard quotient (HQ), and hazard index (HI) of phthalate diesters in 
FT (D7, n = 49; M1, n = 53; M2, n = 54; M3, n = 50; M4, n = 51; M5, n = 50; M6, n = 49; M14, n = 41) and 
PT (D7, n = 38; M1, n = 47; M2, n = 51; M3, n = 58; M4, n = 56; M5, n = 61; M6, n = 61; M14, n = 45) infants 
according to age [day (D) and month (M)]. BW, body weight. Median DIs are shown for the phthalate 
diesters (upper figures), and median levels of HQ and HI (error bars indicate the 25th–75th percentiles) 
are shown for DiBP, DnBP, BBzP, and DEHP (lower figures). The dashed line indicates the antiandrogenic 
threshold value (HI = 1), and values above error bars indicate the percentage of infants exceeding HI (HI 
was defined by summed ratios of estimated daily intakes to TDI based on EFSA recommendations). See 
Supplemental Material, Table S4, for corresponding numeric data.
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et al. 2004; Centers for Disease Control and 
Prevention 2013; Frederiksen et al. 2011).
Phthalates follow a two-step metabolic 
pathway: a phase 1 biotransformation and 
phase 2 conjugation. In the first step, all 
phthalate diesters are hydrolyzed into their 
respective hydrolytic monoesters. The low-
molecular phthalates, such as DEP, DiBP, 
and DnBP, are excreted mainly in urine as 
free or conjugated monoesters, whereas the 
high-molecular monoesters such as MEHP 
and MiNP undergo further biotransformation 
to water-soluble hydroxy- or oxo-metabolites 
before conjugation (Koch and Calafat 2009; 
Rusyn et al. 2006). Phase 2 conjugation is 
catalyzed mainly by uridine 5´-diphospho-
glucuronyl transferase (UGT) to form hydro-
philic glucuronidated conjugates. An alternative 
pathway in high-molecular phthalates is carbox-
ylation of the monoesters. There are about 
20 UGTs, some of which are involved in 
glucuronidation of androgens (Alcorn and 
McNamara 2002), such as UGT2B17, whose 
expression increases significantly during the 
first weeks of life, whereas it is inactive in fetal 
liver cells or present in a low-affinity form 
(Coughtrie et al. 1988; Tan et al. 1990).
It has been proposed that the phthalate 
metabolite excretion pattern of newborns 
could be a consequence of prematurity or 
in utero exposure (Enke et al. 2013). However, 
this metabolitic pattern appeared to persist 
throughout the first year of life in our study 
population, consistent with an immature 
detoxification metabolism. Current risk assess-
ments do not account for this. Because the 
carboxylated metabolite of DEHP has only 
recently become available, previous studies 
on DEHP exposure of newborns may have 
systematically underestimated exposure levels 
(Su et al. 2012; Weuve et al. 2006).
Conclusions
All newborns and infants in our study popu-
lation were exposed to phthalates, not only 
during hospitalization but also at home. Most 
premature babies and up to one-third of 
mature babies in our study population had 
estimated exposures that appeared to exceed 
current EFSA recommendations for daily 
intakes that were developed as guidelines to 
limit the risk of endocrine-disrupting effects. 
Our findings support the need for additional 
research on exposures and health effects of 
phthalates in infants, particularly because 
phthalate metabolism may be limited during 
the first year of life.
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